A Pharmacokinetic Study on the Effect of LY2216684 on the Active Metabolite of Clopidogrel

Exclusion Criteria

• •Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an investigational drug or device or off-label use of a drug or device other than the study drug, or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.
• •Have known allergies to LY2216684, clopidogrel, or related compounds.
• •Are persons who have previously completed or withdrawn from this study or any other study investigating LY2216684 within 6 months prior to screening.
• •Have an abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study.
• •Have a history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data.
• •Have a history of or show evidence of significant active neuropsychiatric disease or have a history of suicide attempt or ideation.
• •Regularly use known drugs of abuse and/or show positive findings on urinary drug screening.
• •Show evidence of human immunodeficiency virus (HIV) and/or positive human HIV antibodies.
• •Show evidence of hepatitis C and/or positive hepatitis C antibody.
• •Show evidence of hepatitis B and/or positive hepatitis B surface antigen.
• •Are women with a positive pregnancy test or women who are lactating.
• •Intend to use over-the-counter or prescription medication within 14 days prior to dosing unless deemed acceptable by the investigator and Sponsor's medical monitor, except for influenza vaccinations.
• •Use of any drugs or substances that are known to be substrates, inducers, or inhibitors of CYP2C19 or CYP3A4 within 30 days prior to dosing.
• •Have donated blood of more than 500 milliliters (mL) within the last month.
• •Have an average weekly alcohol intake that exceeds 14 units per week, or are unwilling to stop alcohol consumption 48 hours prior to check-in until completion of the study (1 unit = 12 ounces \[oz\] or 360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits).
• •Consume 5 or more cups of coffee (or other beverages of comparable caffeine content) per day, on a habitual basis, or any participants unwilling to adhere to study caffeine restrictions.
• •Have used any tobacco-containing or nicotine-containing products (including but not limited to cigarettes, pipes, cigars, chewing tobacco, nicotine patches, nicotine lozenges, or nicotine gum) within 6 months prior to enrollment.
• •Have consumed grapefruit or grapefruit-containing products 7 days prior to enrollment and during the study.
• •Have a documented or suspected history of glaucoma.
• •History or presence of significant bleeding disorders that is, haematemesis, melanena, severe or recurrent epistaxis, haemoptysis, clinically overt clinical haematuria or intracranial haemorrhage.
• •Participants with a history of gastrointestinal ulcers or haemorrhage.
• •Personal or family history of coagulation or bleeding disorders or reasonable suspicion of vascular malformations, for example, cerebral haemorrhage, aneurysm or premature stroke (cerebrovascular accident \<65 years of age).
• •Self-reported history of increased bleeding from trauma (for example, prolonged bleeding after tooth extraction).
• •History of major surgery within 3 months of screening.
• •Planned surgery within 14 days after the last day of dosing.
• •International normalized ratio (INR), prothrombin time (PT), activated partial thromboplastin time (APTT) above the normal reference range or platelet count below the normal reference range at screening.
• •Positive fecal occult blood examination at screening.
• •Clinically significant abnormality in fundoscopic or petechiae examination.
• •Consumption of aspirin, other non-steroidal anti-inflammatory drugs or other drugs known to affect platelet function within 21 days prior to dosing.
• •Participants determined to be unsuitable by the investigator for any reason.